Search

Author/Creator Strickland, Stephen A

1. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Issue 7 (July 2021)

Authors:
Lancet, Jeffrey E; Uy, Geoffrey L; Newell, Laura F; Lin, Tara L; Ritchie, Ellen K; Stuart, Robert K; Strickland, Stephen A; Hogge, Donna; Solomon, Scott R; Bixby, Dale L; Kolitz, Jonathan E; Schiller, Gary J; Wieduwilt, Matthew J; Ryan, Daniel H; Faderl, Stefan; Cortes, Jorge E
Journal:
Lancet
Issue:
Volume 8:Issue 7(2021)
Page Start:
e481
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials. (August 2017)

Authors:
Strickland, Stephen A; Sun, Zhuoxin; Ketterling, Rhett P; Cherry, Athena M; Cripe, Larry D; Dewald, Gordon; Fernandez, Hugo F; Hicks, Gary A; Higgins, Rodney R; Lazarus, Hillard M; Litzow, Mark R; Luger, Selina M; Paietta, Elisabeth M; Rowe, Jacob M; Vance, Gail H; Wiernik, Peter; Wiktor, Anne E;...
Journal:
Leukemia research
Issue:
Volume 59(2017:Aug.)
Page Start:
55
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. Issue 8 (August 2017)

Authors:
Perl, Alexander E; Altman, Jessica K; Cortes, Jorge; Smith, Catherine; Litzow, Mark; Baer, Maria R; Claxton, David; Erba, Harry P; Gill, Stan; Goldberg, Stuart; Jurcic, Joseph G; Larson, Richard A; Liu, Chaofeng; Ritchie, Ellen; Schiller, Gary; Spira, Alexander I; Strickland, Stephen A; Tibes, Ra...
Journal:
Lancet oncology
Issue:
Volume 18:Issue 8(2017:Aug.)
Page Start:
1061
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Issue 9 (September 2015)

Authors:
Ravandi, Farhad; Ritchie, Ellen K; Sayar, Hamid; Lancet, Jeffrey E; Craig, Michael D; Vey, Norbert; Strickland, Stephen A; Schiller, Gary J; Jabbour, Elias; Erba, Harry P; Pigneux, Arnaud; Horst, Heinz-August; Recher, Christian; Klimek, Virginia M; Cortes, Jorge; Roboz, Gail J; Odenike, Olatoyosi...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 9(2015:Sep.)
Page Start:
1025
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Issue 9 (September 2015)

Authors:
Ravandi, Farhad; Ritchie, Ellen K; Sayar, Hamid; Lancet, Jeffrey E; Craig, Michael D; Vey, Norbert; Strickland, Stephen A; Schiller, Gary J; Jabbour, Elias; Erba, Harry P; Pigneux, Arnaud; Horst, Heinz-August; Recher, Christian; Klimek, Virginia M; Cortes, Jorge; Roboz, Gail J; Odenike, Olatoyosi...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 9(2015:Sep.)
Page Start:
1025
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗